The SAS subsidiary's new enhancement leverages vastly expanded consumer rate shopping data, offering hoteliers granular visibility across room types and distribution channels to refine pricing strategies.
Despite a premium valuation, AMD is positioning itself as a key challenger in the AI chip race, betting big on integrated data center systems to capture surging demand.
Bloom Energy's stock surged after American Electric Power's subsidiary locked in a massive 20-year fuel cell agreement, a move analysts say validates the company's technology for critical infrastructure like AI data centers and signals a pivotal shift in its growth narrative.
Brookfield Infrastructure Partners capped a strong 2025 with double-digit FFO growth, a record capital recycling program, and a raised distribution. Management highlighted a massive, disciplined expansion in data infrastructure to meet AI-driven demand, forecasting a return to 10%+ growth targets.
As Insmed prepares to unveil key data for its TPIP program at a major medical congress, fresh analyst coverage highlights the treatment's potential to reshape the company's future. Amidst a volatile stock performance, investors are weighing high-growth prospects against persistent financial risks.
The Labor Department has postponed the release of January's highly anticipated employment report, citing the ongoing partial government shutdown. This marks the second major delay in recent months for a key economic indicator that markets and policymakers rely on.
A new analysis examines whether ultra-long home loans can solve the affordability crisis. While they offer a monthly payment reprieve in select markets, the long-term financial toll is staggering, raising questions about who truly benefits.
A California class-action lawsuit and regulatory actions are challenging Tesla's usage-based insurance model, alleging that its Safety Score algorithm unfairly penalizes drivers with 'false' collision warnings. The case highlights broader concerns about transparency and consumer protection in the growing telematics-driven insurance sector.
An analysis of President Trump's recent op-ed claims reveals significant discrepancies between his portrayal of tariff success and official trade figures, price impact studies, and the nuanced reality of their implementation.
H.C. Wainwright maintains a Buy rating on Lexeo Therapeutics but slashes its price target, citing persistent market doubts over the company's PKP2 cardiomyopathy program despite encouraging early clinical results.
As Nvidia prepares to report its fiscal Q4 earnings on February 25th, investors are weighing whether to buy ahead of the event. While the AI chip leader's long-term story remains compelling, a look at its recent post-earnings stock performance reveals a pattern that favors a measured approach over trying to time the market.
U.S. stock futures pointed to a lower open Monday as investors braced for a flood of corporate earnings and crucial labor market reports that could sway Federal Reserve policy expectations.
A coalition of major international NGOs is refusing to comply with Israeli orders to hand over detailed staff information, calling it a safety risk and an obstruction of aid, as tensions escalate following the expulsion of Médecins Sans Frontières.
CNBC's Jim Cramer scrutinizes Bitcoin's sharp retreat from the $80,000 milestone, casting doubt on the durability of its support and highlighting a market driven more by narrative than fundamentals.
As Bitcoin grapples with volatility below $80,000, a packed U.S. economic calendar—featuring key jobs reports and MicroStrategy's Q4 earnings—is poised to dictate the cryptocurrency's near-term trajectory by shaping Federal Reserve policy expectations.
The decentralized finance protocol has publicly identified wallets linked to a weekend exploit, warning of criminal and civil action if funds are not returned within 72 hours, as security firms point to a critical validation flaw.
As Israel now acknowledges over 70,000 killed in Gaza, rights advocates argue that early Western political and media skepticism dehumanized Palestinians and delayed a full reckoning with the war's human cost.
The Israeli government has ordered Médecins Sans Frontières (MSF) to cease operations in Gaza by the end of February, citing the aid group's refusal to hand over details of its Palestinian staff—a move critics decry as a dangerous politicization of humanitarian aid.
New long-term results from the pivotal EMBARK trial indicate ELEVIDYS, Sarepta's gene therapy, continues to alter the disease trajectory for boys with Duchenne muscular dystrophy, with no new safety concerns emerging over three years.
Atlassian confronts a mounting identity theft campaign targeting its systems while rival Anthropic launches a competing AI collaboration tool, adding pressure to a stock already down over 50% in the past year.
